 -- Collaboration expected to accelerate access to Evelos lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Healths first biotechnology licensing agreement 